 | • レポートコード：MRC2203A185 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のコレラワクチン市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、ワクチン種類別（組換えBサブユニット含有全細胞コレラ菌O1、不活化口頭O1・O139）分析、製品別（Vaxchora、デュコラル、シャンコール、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のコレラワクチン市場規模：ワクチン種類別（組換えBサブユニット含有全細胞コレラ菌O1、不活化口頭O1・O139） ・世界のコレラワクチン市場規模：製品別（Vaxchora、デュコラル、シャンコール、その他） ・世界のコレラワクチン市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Astellas Pharma Inc.、Emergent BioSolutions Inc.、GlaxoSmithKline plc (GSK)、…） ・市場機会・将来傾向 |
The growth of the global cholera vaccines market can be attributed to multiple factors, such as the increasing incidences of cholera, rising initiatives by public and private entities, and growing awareness regarding cholera across the world. In 2017, 10 million doses of oral cholera vaccines were funded in affected countries via stockpile. This stockpile has been accessed 52 times since the funding, by 18 countries across the world, including Sierra Leone and Haiti. However, a lack of access to adequate care for cholera, coupled with a large number of unreported cases, are expected to pull back the growth of the market.
Key Market Trends
Whole-cell V. cholerae O1 with a Recombinant B-subunit Segment Captures the Largest Market Share
This oral cholera vaccine containing a combination of recombinant B-subunit and killed whole cell V. cholerae O1 has been marketed since early 1990. This vaccine is observed to provide 80-90% protection for six months, post immunization, and in all the cases of immunization of vaccines aged more than 2 years. In addition to this, this vaccines shows around 50% of protection even after three years of immunization. Hence, the efficacy and long-lasting post immunization protections of the vaccine are expected to propel the segment’s growth over the forecast period.
Asia-Pacific is Expected to Grow at a High Rate over the Forecast Period
- Asia-Pacific captures the largest market share in the global cholera vaccines market, followed by Europe. This can be attributed to the high incidence rate, growing awareness, and availability of efficient preventive solutions.
- The APAC market experienced exceptional growth since the launch of the oral cholera vaccine, Shanchol.
- According to the statistics of WHO, 12 countries in Asia reported with cholera which constituted about 13% of cases in the total cases worldwide. This statistics showed an overall decrease of 9% from the previous year, owing to growing immunization in the region.
- On the other hand, North America is expected to exhibit the fastest growth rate over the forecast period, owing to the launch of the first ever oral cholera vaccine, Vaxchora, in 2016, and the rise in the number of immigrants.
Competitive Landscape
Some of the significant companies in the market are AstraZeneca, Shantha Biotechnics Private Limited, Valneva SE, Merck & Co. Inc., and PaxVax Inc. The major market players, in order to retain a strong market position, focus on mergers, acquisitions, and product innovation. Also, licensing rights on the vaccines of some major companies give them the leverage of a strong market foothold. For instance, the licensing rights of Dukoral were conferred to Valneva SE, post-acquisition of Crucell Sweden AB, in turn, strengthening the company’s cholera vaccine portfolio and overall market position.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Cholera
4.2.2 Rising Initiatives and Awareness Regarding Immunization
4.3 Market Restraints
4.3.1 Lack of Access to Adequate Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Vaccine Type
5.1.1 Whole cell V. cholerae O1 with Recombinant B-subunit
5.1.2 Killed Oral O1 and O139
5.2 Product
5.2.1 Vaxchora
5.2.2 Dukoral
5.2.3 Shanchol
5.2.4 Other Products
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Astellas Pharma Inc.
6.1.2 Emergent BioSolutions Inc.
6.1.3 GlaxoSmithKline plc (GSK)
6.1.4 Merck & Co. Inc.
6.1.5 Mitsubishi Tanabe Pharma Corporation
6.1.6 Sanofi
6.1.7 Takeda Pharmaceutical Co. Ltd
6.1.8 Valneva SE
7 MARKET OPPORTUNITIES AND FUTURE TRENDS